Resverlogix is a Calgary biotechnology company developing small-molecule therapies that target epigenetic mechanisms involved in cardiovascular, metabolic, and inflammatory disease. Public company materials have long centered on bromodomain and extra-terminal protein inhibition and on its lead clinical program, apabetalone. The company’s positioning is that of a clinical-stage developer pursuing novel mechanisms in serious chronic diseases.